ATE313333T1 - Verwendung eines leukämie-hemmenden faktor antagonisten - Google Patents

Verwendung eines leukämie-hemmenden faktor antagonisten

Info

Publication number
ATE313333T1
ATE313333T1 AT02016730T AT02016730T ATE313333T1 AT E313333 T1 ATE313333 T1 AT E313333T1 AT 02016730 T AT02016730 T AT 02016730T AT 02016730 T AT02016730 T AT 02016730T AT E313333 T1 ATE313333 T1 AT E313333T1
Authority
AT
Austria
Prior art keywords
leukemia
antagonist
factor antagonist
inhibiting factor
administered
Prior art date
Application number
AT02016730T
Other languages
English (en)
Inventor
Napoleone Ferrara
Kathleen King
Elizabeth A Luis
Jennie P Mather
Nicholas F Paoni
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE313333T1 publication Critical patent/ATE313333T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT02016730T 1995-04-24 1996-04-17 Verwendung eines leukämie-hemmenden faktor antagonisten ATE313333T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42738395A 1995-04-24 1995-04-24

Publications (1)

Publication Number Publication Date
ATE313333T1 true ATE313333T1 (de) 2006-01-15

Family

ID=23694642

Family Applications (2)

Application Number Title Priority Date Filing Date
AT96913814T ATE233570T1 (de) 1995-04-24 1996-04-17 Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten
AT02016730T ATE313333T1 (de) 1995-04-24 1996-04-17 Verwendung eines leukämie-hemmenden faktor antagonisten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT96913814T ATE233570T1 (de) 1995-04-24 1996-04-17 Verwendung des leukämie-inhibitor-faktor und endothelin antagonisten

Country Status (12)

Country Link
EP (2) EP1287832B1 (de)
JP (1) JPH11504332A (de)
AT (2) ATE233570T1 (de)
AU (1) AU702375B2 (de)
CA (1) CA2214636C (de)
DE (2) DE69635630T2 (de)
DK (2) DK0830143T3 (de)
ES (1) ES2254564T3 (de)
IL (1) IL117998A (de)
MX (1) MX9707939A (de)
WO (1) WO1996033740A1 (de)
ZA (1) ZA963274B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000001404A1 (en) 1998-07-06 2000-01-13 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Compositions and methods for $i(in vitro) fertilization
EP1549198A4 (de) * 2002-09-30 2007-03-28 Univ Duke Thymusatrophi
JP2011231014A (ja) * 2008-08-27 2011-11-17 Keiichi Fukuda 心不全の治療剤
EP2371860A1 (de) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Den humanen leukaemieinhibierenden Faktor (LIF) erkennender Antikörper und Verwendung von LIF-Antikörpern bei der Behandlung von Krankheiten im Zusammenhang mit ungewollter Zellproliferation
SI3555132T1 (sl) 2016-12-19 2024-04-30 Medimmune Limited Protitelesa proti LIF in njihove uporabe
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4231393A (en) * 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
WO1995008550A1 (en) * 1993-09-24 1995-03-30 Abbott Laboratories Endothelin antagonists

Also Published As

Publication number Publication date
AU702375B2 (en) 1999-02-18
CA2214636C (en) 2009-12-22
EP1287832A3 (de) 2003-04-16
EP0830143B1 (de) 2003-03-05
EP0830143A1 (de) 1998-03-25
DE69626510D1 (de) 2003-04-10
ZA963274B (en) 1997-10-24
WO1996033740A1 (en) 1996-10-31
MX9707939A (es) 1997-12-31
JPH11504332A (ja) 1999-04-20
DE69635630D1 (de) 2006-01-26
ATE233570T1 (de) 2003-03-15
DE69635630T2 (de) 2006-08-10
DK1287832T3 (da) 2006-05-01
DK0830143T3 (da) 2003-06-16
EP1287832A2 (de) 2003-03-05
CA2214636A1 (en) 1996-10-31
IL117998A0 (en) 1996-08-04
ES2254564T3 (es) 2006-06-16
IL117998A (en) 2001-04-30
EP1287832B1 (de) 2005-12-21
DE69626510T2 (de) 2003-12-11
AU5665896A (en) 1996-11-18

Similar Documents

Publication Publication Date Title
BR9915164A (pt) Tratamento de malignidades hematológicas associadas com células de tumor circulantes usando anticorpo anti-cd20 quimérico
WO2001009138A3 (en) Chemokine receptor antagonists and methods of use therefor
DK0661973T3 (da) Fremgangsmåde til forebyggelse af NMDA-receptorkompleksmedieret neuronskade
MX9804597A (es) Derivados de bencimidazol sustituidos por naftilo como anticoagulantes.
FI880349A7 (fi) Kiinnitysjärjestelmä katetrien, kanyylien tai vastaavien kiinnittämiseksi ihon pintaan
DK0402068T3 (da) Polypeptider og polypeptidanaloger med inhiberende virkning mod human elastase
AR244492A1 (es) Composicion fungicida mejorada para el tratamiento de la madera.
IT8983533A0 (it) Dispositivo per la regolazione del frontale nei cassetti
ATE202599T1 (de) Mit isoliertem empfindlichem x-syndrom verbundene dns-sequenzen
DK0498144T3 (da) Anvendelse af acetyl-L-carnitin ved terapeutisk behandling af coma
DE69635630D1 (de) Verwendung eines Leukämie-hemmenden Faktor Antagonisten
ATE231131T1 (de) Verbindungen mit wachtumshormon freisetzenden eigenschaften
DK578887D0 (da) Antihypertensiva
BR9708525A (pt) Método de tratamento de insuficência cardíaca com antagonistas de endotelina
NO990450L (no) Behandling av sinnslidelser
DK0862454T3 (da) CTLA-8 i kombination med G-CSF eller med G-CSF og IL-6 og anvendelse af CTLA-8 til behandling af infektioner
WO2001009119A3 (en) Chemokine receptor antagonists
BR0009644A (pt) Tratamento de carcinoma de célula renal
IT8519042A0 (it) Impiego di chinoloni nel trattamento di malattie cardiache.!
IT8819286A0 (it) Procedimento per il trattamento extracorporeo di liquido ascitico.
FI952018A0 (fi) BHAP-yhdisteiden käyttö yhdessä muiden ei-nukleosidi-käänteistransskriptaasi-inhibiittoreiden kanssa HIV-infektion hoitoon
IT233634Y1 (it) Tavoletta filtro per cannule di gruppi di aspirazione dentistici.
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
MX12192A (es) Composicion farmaceutica para reducir o impedir las arritmias
BR0009642A (pt) Terapia de leucemia mielocìtica crÈnica

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1287832

Country of ref document: EP

REN Ceased due to non-payment of the annual fee